RVNC — Revance Therapeutics Share News
0.000.00%
Last trade - 00:00- $379.98m
- $637.94m
- $234.04m
AbbVie expects Botox market share to stay strong despite newer rivals (updated)
Brief: Revance Provides Financial Outlook
Revance Therapeutics down as Q4 prelim sales, annual forecast fall below ests
Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit
US Consumer group seeks stronger warnings on Botox, similar treatments
U.S. RESEARCH ROUNDUP-Clorox, GoDaddy, Reynolds Consumer Products
Brief: Revance Therapeutics Q3 EPS USD -1.63
Revance Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Bausch Health Companies, Chewy, First Citizens Bancshares
U.S. STOCKS ON THE MOVE-Starbucks, Instacart, Dish
Revance Therapeutics falls on plans to price Botox rival at discount
Brief: Revance Provides Corporate Update At Investor Day
Brief: Revance Therapeutics Commenced A Plan To Exit Opul Payments Business
'Barbie Botox' goes viral but doctors inject caution (updated)
Brief: Teoxane SA Reports 5.0% Stake In Revance Therapeutics As Of August 22
'Barbie Botox' goes viral but doctors inject caution
U.S. STOCKS ON THE MOVE-Nvidia, Westlake, North American steel companies
U.S. STOCKS ON THE MOVE-TMC, PayPal, TOMI
Revance rises on FDA approval for treatment of painful neck muscle condition